this has baffled me also. the research i did to see when a
this has baffled me also. the research i did to see when a small biotech gets partnered or bought out by BP showed that it is in phase 2. BP does not care about phase 1 and phase 3 just means the company could not get a partnership in phase 2. Also, buy outs occur typically after there has been some sort of partnership in place for awhile. BP dips there toes first and sees if there is really something there before the buy out.
However, it seems that in the past few years, BP has changed an is much more conservative. They have gotten burned buy phase 2 drugs too many times and it cost billions to make that mistake. I also feel there is a lot of small biotechs that are born out of ex executives from a BP and they already have the fix on a buy out from day one.
Cytodyn is a garage band and has played this poorly. early on I think they would just get a phone call from BP and the deal would be done. That did not happen and they just kept truck'n along and blew right through the phase 2 window of opportinity and solidly put themselves in the "go it alone" camp. they did not have BP connections and they were looking way further down the horizon. This is good if you want maximum potential, but it is obviously a long bumpy road. the other good thing is they would never have know Leronlimab is a cancer, covid and Nash drug if they has been dealmakers with HIV at phase 2.
I just don't know how BP is so out of the picture on this, they likely are talking to them, but most of the typical signs of a major partnership or buy out seem to no more than theorys or rumor. maybe Nader getting canned is a way to not only get on track with the FDA but also with partners, I hope that is the outcome!
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Bold Play in the Global Arena There's something big brewing on the horizon, as Haier aligns with the UEFA Champions League. From 2027 to 2031, this move isn't just about slapping a logo on a jersey. Nah, it's more than that. Haier's stepping up its game, aiming to become a real player in weaving technology and sports into the daily lives of millions. "We aim to bring...
Continue Reading
Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...
Continue Reading
Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...
Continue Reading
Public Charity Expands Into Education Well, here's something that's bound to turn a few heads: a fast-growing public charity has just made its first acquisition in the K-12 sphere by snapping up Wayfinder. The stakes are getting interesting. When a charity starts playing in the acquisition space, you're looking at a change in strategy that deserves close attention. Why...
Continue Reading
Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...
Continue Reading
Adapt or Get Left Behind: The Texas Insurance Scene In a world where costs are ballooning and the pressure on the wallet grows heavier, here comes Bamboo Insurance swinging into Texas like a hopeful knight. This plucky insurer is rolling out the Texas Essential Homeowner Program, a highly adaptable, admitted policy that promises to put some power back into the hands of...
Continue Reading
Legal Storm Brewing with AEVEX's IPO Disclosures Whatever happened to straightforward honesty in business? AEVEX Corp. (NYSE: AVEX) might have forgotten that chapter judging by fresh allegations in their midst. Investors who bought AVEX Class A common stock between April 17 and June 4, 2026, have been hit with a curveball: a looming class action lawsuit for securities...
Continue Reading
An Uptick in BTC Staking Yields Seems like Bybit's got a trick up their sleeve with their latest move. They've hiked BTC staking yields from a static 0.8% up to a more attractive 1.2%. Now, if you're parked with Bitcoin in this dicey market, that's a substantial 50% leap upwards. When you think about those dreamy numbers traders like me fantasize about, it’s a juicy...
Continue Reading
MINISFORUM's Bold Move in Edge AI Computing There's no doubt that 2026 is about AI making its way to the forefront, and MINISFORUM is moving full steam ahead. Introduced at the IFA in Berlin, MINISFORUM unveiled its latest input into the edge AI scene with the AMD Ryzen AI MAX+ PRO 495 driving the charge. Now, these aren't just ordinary upgrades, mind you. We're talking...
Continue Reading
Halloween's New Twist with Gemmy's Animatronics Well, just when you thought Halloween couldn't get any more over the top, here comes Gemmy with their 3-foot tall animatronic characters ready to give your trick-or-treat scene that extra jolt. These aren't just any run-of-the-mill decorations. Nope, they come with a twist—an industrial-strength twist of scares and sweets...
Continue Reading
Top 5 Most Recently Viewed Articles
Incyte Faces Challenges Ahead of Patent Expiration Truist Securities has taken a cautious stance by downgrading Incyte Corporation (NASDAQ: INCY), voicing worries over the upcoming patent expiry of Jakafi in 2028. This downgrade underscores the necessity for Incyte to craft an effective strategy as it deals with a competitive environment. Jakafi's Importance Jakafi,...
Continue Reading
Halper Sadeh LLC Investigates Staffing 360 Sale Halper Sadeh LLC, a law firm dedicated to protecting investor rights, has initiated an investigation regarding the sale of Staffing 360 Solutions, Inc. (NASDAQ: STAF) to Atlantic International Corp. This scrutiny centers on whether the terms of the sale, which involves exchanging 1.202 Atlantic shares for each share of...
Continue Reading
FranNet just named Amanda Duplantis as President on February 17, 2026, and you know what that means for the franchise landscape. She’s stepping into some big shoes, taking over day-to-day operations while promising to pump fresh life into a firm that's been at this game for decades. Traders are already buzzing about her leadership style—Duplantis isn’t new to this...
Continue Reading
RCI Hospitality Holdings, Inc. Reports Fourth Quarter and Year End Results RCI Hospitality Holdings, Inc. (Nasdaq: RICK) has recently unveiled its results for the fiscal fourth quarter and the entire fiscal year of 2024, ending September 30, 2024. The company presented a thorough overview of its financial performance, highlighted by strategic insights on growth and...
Continue Reading
Understanding the Class Action Opportunity In the investment world, navigating securities can pose significant challenges for shareholders. If you have purchased securities from Iris Energy Limited (NASDAQ: IREN), there’s an opportunity for you to get involved in a class action lawsuit. This suits individuals who bought shares during the designated class period, where...
Continue Reading